Targeting Inhibition of Fibroblast Activation Protein-α and Prolyl Oligopeptidase Activities on Cells Common to Metastatic Tumor Microenvironments

被引:42
|
作者
Christiansen, Victoria J.
Jackson, Kenneth W.
Lee, Kyung N.
Downs, Tamyra D.
McKee, Patrick A.
机构
[1] Univ Oklahoma, Coll Med, William K Warren Med Res Ctr, Oklahoma City, OK 73190 USA
[2] Univ Oklahoma, Coll Med, Dept Med, Oklahoma City, OK 73190 USA
来源
NEOPLASIA | 2013年 / 15卷 / 04期
基金
美国国家卫生研究院;
关键词
POTENTIAL THERAPEUTIC TARGET; ANTIPLASMIN-CLEAVING ENZYME; MESENCHYMAL STEM-CELLS; SERINE-PROTEASE; HUMAN BONE; DIPEPTIDYLPEPTIDASE-IV; STROMAL FIBROBLASTS; MOLECULAR-CLONING; EXPRESSION; OVEREXPRESSION;
D O I
10.1593/neo.121850
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Fibroblast activation protein (FAP), a membrane prolyl-specific proteinase with both dipeptidase and endopeptidase activities, is overexpressed by reactive stromal fibroblasts during epithelial-derived cancer growth. FAP digests extracellular matrix as tissue is remodeled during cancer expansion and may also promote an immuno-tolerant tumor microenvironment. Recent studies suggest that nonspecific FAP inhibitors suppress human cancer xenografts in mouse models. Prolyl oligopeptidase ( POP), another prolyl-specific serine proteinase, is also elevated in many cancers and may have a regulatory role in angiogenesis promotion. FAP and POP cell-associated activities may be targets for diagnosis and treatment of various cancers, but their accessibilities to highly effective specific inhibitors have not been shown for cells important to cancer growth. Despite their frequent simultaneous expression in many cancers and their overlapping activities toward commonly used substrates, precise, separate measurement of FAP or POP activity has largely been ignored. To distinguish each of the two activities, we synthesized highly specific substrates and inhibitors for FAP or POP based on amino acid sequences surrounding the scissile bonds of their respective putative substrates. We found varying amounts of FAP and POP protein and activities on activated fibroblasts, mesenchymal cells, normal breast cells, and one breast cancer cell line, with some cells exhibiting more POP than FAP activity. Replicating endothelial cells (ECs) expressed POP but not FAP until tubulogenesis began. Targeting FAP-positive cells, especially mesenchymal stem cells and cancer-associated fibroblasts for inactivation or destruction, and inhibiting POP-producing EC may abrogate stromal invasion and angiogenesis simultaneously and thereby diminish cancer growth.
引用
收藏
页码:348 / 358
页数:11
相关论文
共 50 条
  • [41] Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton
    Barkan, Dalit
    Kleinman, Hynda
    Simmons, Justin L.
    Asmussen, Holly
    Kamaraju, Anil K.
    Hoenorhoff, Mark J.
    Liu, Zi-yao
    Costes, Sylvain V.
    Cho, Edward H.
    Lockett, Stephen
    Khanna, Chand
    Chambers, Ann F.
    Green, Jeffrey E.
    CANCER RESEARCH, 2008, 68 (15) : 6241 - 6250
  • [42] Specific inhibition of fibroblast activation protein (FAP)-alpha prevents tumor progression in vitro
    Teichgraeber, Volker
    Monasterio, Carmen
    Chaitanya, Krishna
    Boger, Regina
    Gordon, Katrin
    Dieterle, Thomas
    Jaeger, Dirk
    Bauer, Stefan
    ADVANCES IN MEDICAL SCIENCES, 2015, 60 (02): : 264 - 272
  • [43] Inhibition of tumor growth by novel CART redirected against cells expressing high levels of fibroblast activation protein.
    Noguera-Ortega, Estela
    Todd, Leslie
    Monslow, James
    Sun, Jing
    Albelda, Steven M.
    Pure, Ellen
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (03) : 62 - 62
  • [44] Metastasis prevention using fibroblast activation protein-targeting prodrugs at the pre-metastatic niche
    Murgai, Meera
    Giles, Amber
    Kasai, Miki
    Vicioso, Yorleny
    Mackall, Crystal
    Kaplan, Rosandra
    CANCER RESEARCH, 2014, 74 (19)
  • [45] Depleting cells expressing fibroblast activation protein disrupts tumor promoting desmoplasia
    Lo, Albert
    Wang, Liang-Chuan S.
    Scholler, John
    Monslow, James
    Avery, Diana
    Evans, Rebecca A.
    Bajor, David J.
    Durham, Amy C.
    Buza, Elizabeth L.
    Vonderheide, Robert H.
    June, Carl H.
    Albelda, Steven M.
    Pure, Ellen
    CANCER RESEARCH, 2015, 75
  • [46] Deletion or inhibition of prolyl oligopeptidase blocks lithium-induced phosphorylation of GSK3b and Akt by activation of protein phosphatase 2A
    Myohanen, Timo T.
    Mertens, Freke
    Norrbacka, Susanna
    Cui, Hengjing
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2021, 129 (04) : 287 - 296
  • [47] Spatial expression of fibroblast activation protein-α in clear cell renal cell carcinomas revealed by multiplex immunoprofiling analysis of the tumor microenvironment
    Larrinaga, Gorka
    Redrado, Miriam
    Loizaga-Iriarte, Ana
    Perez-Fernandez, Amparo
    Santos-Martin, Aida
    Angulo, Javier C.
    Fernandez, Jose A.
    Calvo, Alfonso
    Lopez, Jose I.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2025, 74 (02)
  • [48] Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia
    Roberts, Edward W.
    Deonarine, Andrew
    Jones, James O.
    Denton, Alice E.
    Feig, Christine
    Lyons, Scott K.
    Espeli, Marion
    Kraman, Matthew
    McKenna, Brendan
    Wells, Richard J. B.
    Zhao, Qi
    Caballero, Otavia L.
    Larder, Rachel
    Coll, Anthony P.
    O'Rahilly, Stephen
    Brindle, Kevin M.
    Teichmann, Sarah A.
    Tuveson, David A.
    Fearon, Douglas T.
    JOURNAL OF EXPERIMENTAL MEDICINE, 2013, 210 (06): : 1137 - 1151
  • [49] Short hairpin RNA targeting of fibroblast activation protein inhibits tumor growth and improves the tumor microenvironment in a mouse model
    Cai, Fan
    Li, Zhiyong
    Wang, Chunting
    Xian, Shuang
    Xu, Guangchao
    Peng, Feng
    Wei, Yuquan
    Lu, You
    BMB REPORTS, 2013, 46 (05) : 252 - 257
  • [50] Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model
    Wen, Yuan
    Wang, Chun-Ting
    Ma, Tian-Tai
    Li, Zhi-Yong
    Zhou, Li-Na
    Mu, Bo
    Leng, Fei
    Shi, Hua-Shan
    Li, Ya-Ou
    Wei, Yu-Quan
    CANCER SCIENCE, 2010, 101 (11) : 2325 - 2332